Related Experiment Video
Updated: May 4, 2026
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
17.1K
Antithrombin III Utilization in a Large Teaching Hospital.
P & T : a Peer-Reviewed Journal for Formulary Management
|January 7, 2014
Summary
For hereditary antithrombin deficiency, plasma-derived antithrombin concentrates (Thrombate III) are more cost-effective than recombinant human antithrombin (ATryn). This finding aids treatment decisions for this rare genetic disorder.
Area of Science:
- Pharmacoeconomics
- Hematology
- Genetics
Background:
- Hereditary antithrombin deficiency is a rare genetic disorder increasing thrombotic risk.
- Antithrombin concentrates are crucial for managing thrombotic events in these patients.
- Two main types of antithrombin concentrates exist: plasma-derived and recombinant human.
Purpose of the Study:
- To compare the cost-effectiveness of plasma-derived antithrombin concentrates versus recombinant human antithrombin.
- To inform clinical and economic decision-making for hereditary antithrombin deficiency management.
Main Methods:
- Retrospective study design.
- Analysis of cost-effectiveness data for Thrombate III and ATryn.
- Evaluation of treatment costs associated with hereditary antithrombin deficiency.
Main Results:
- Plasma-derived antithrombin (Thrombate III) was found to be more cost-effective.
- The study identified significant cost differences between the two concentrate types.
Conclusions:
- Thrombate III presents a more economical option for managing hereditary antithrombin deficiency compared to ATryn.
- Cost-effectiveness should be a key consideration in selecting antithrombin therapy for this patient population.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:30Venous Thrombosis IV: Nursing Management
415
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
415
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:27Pulmonary Embolism III: Nursing Management
756
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
756
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
749
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
749